Immunocore Holdings plc (NASDAQ:IMCR) Short Interest Update

Immunocore Holdings plc (NASDAQ:IMCR) was the recipient of a significant increase in short interest in January. As of January 31st, there was short interest totalling 7,340,000 shares, an increase of 9.4% from the January 15th total of 6,710,000 shares. Approximately 15.1% of the shares of the stock are short sold. Based on an average daily trading volume, of 264,000 shares, the days-to-cover ratio is presently 27.8 days.

Hedge Funds Weigh In On Immunocore

A number of institutional investors have recently made changes to their positions in the stock. Exchange Traded Concepts LLC increased its stake in Immunocore by 40.4% in the third quarter. Exchange Traded Concepts LLC now owns 5,075 shares of the company’s stock valued at $158,000 after purchasing an additional 1,461 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its stake in Immunocore by 69.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 7,433 shares of the company’s stock valued at $231,000 after purchasing an additional 3,053 shares during the last quarter. NEOS Investment Management LLC increased its stake in Immunocore by 10.9% in the fourth quarter. NEOS Investment Management LLC now owns 11,194 shares of the company’s stock valued at $330,000 after purchasing an additional 1,102 shares during the last quarter. Virtus ETF Advisers LLC increased its stake in Immunocore by 39.0% in the fourth quarter. Virtus ETF Advisers LLC now owns 11,536 shares of the company’s stock valued at $340,000 after purchasing an additional 3,238 shares during the last quarter. Finally, GSA Capital Partners LLP acquired a new position in Immunocore in the third quarter valued at $406,000. 84.50% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on IMCR shares. Morgan Stanley restated an “equal weight” rating and issued a $35.00 price target (down from $74.00) on shares of Immunocore in a research note on Friday, December 13th. Mizuho downgraded Immunocore from an “outperform” rating to a “neutral” rating and decreased their target price for the stock from $72.00 to $38.00 in a research report on Monday, November 11th. UBS Group initiated coverage on Immunocore in a research report on Thursday, October 24th. They set a “sell” rating and a $24.00 target price on the stock. HC Wainwright reiterated a “buy” rating and set a $100.00 target price on shares of Immunocore in a research report on Monday, January 27th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $71.00 target price on shares of Immunocore in a research report on Friday, January 10th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $65.64.

Immunocore Stock Performance

Shares of NASDAQ IMCR traded down $0.14 during trading on Friday, reaching $29.60. The company had a trading volume of 90,945 shares, compared to its average volume of 225,403. Immunocore has a twelve month low of $27.69 and a twelve month high of $73.16. The stock has a 50-day moving average price of $30.08 and a two-hundred day moving average price of $32.43. The company has a debt-to-equity ratio of 1.03, a quick ratio of 3.76 and a current ratio of 3.78.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.